332 related articles for article (PubMed ID: 11967034)
1. Sodium ferric gluconate complex in hemodialysis patients: adverse reactions compared to placebo and iron dextran.
Michael B; Coyne DW; Fishbane S; Folkert V; Lynn R; Nissenson AR; Agarwal R; Eschbach JW; Fadem SZ; Trout JR; Strobos J; Warnock DG;
Kidney Int; 2002 May; 61(5):1830-9. PubMed ID: 11967034
[TBL] [Abstract][Full Text] [Related]
2. Sodium ferric gluconate complex in hemodialysis patients. II. Adverse reactions in iron dextran-sensitive and dextran-tolerant patients.
Coyne DW; Adkinson NF; Nissenson AR; Fishbane S; Agarwal R; Eschbach JW; Michael B; Folkert V; Batlle D; Trout JR; Dahl N; Myirski P; Strobos J; Warnock DG;
Kidney Int; 2003 Jan; 63(1):217-24. PubMed ID: 12472786
[TBL] [Abstract][Full Text] [Related]
3. The comparative safety of various intravenous iron preparations in chronic kidney disease patients.
Anirban G; Kohli HS; Jha V; Gupta KL; Sakhuja V
Ren Fail; 2008; 30(6):629-38. PubMed ID: 18661414
[TBL] [Abstract][Full Text] [Related]
4. Chronic use of sodium ferric gluconate complex in hemodialysis patients: safety of higher-dose (> or =250 mg) administration.
Folkert VW; Michael B; Agarwal R; Coyne DW; Dahl N; Myirski P; Warnock DG;
Am J Kidney Dis; 2003 Mar; 41(3):651-7. PubMed ID: 12612989
[TBL] [Abstract][Full Text] [Related]
5. Sodium ferric gluconate complex in haemodialysis patients: a prospective evaluation of long-term safety.
Michael B; Coyne DW; Folkert VW; Dahl NV; Warnock DG;
Nephrol Dial Transplant; 2004 Jun; 19(6):1576-80. PubMed ID: 15034152
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sodium ferric gluconate complex in patients with chronic kidney disease.
Panesar A; Agarwal R
Am J Kidney Dis; 2002 Nov; 40(5):924-31. PubMed ID: 12407636
[TBL] [Abstract][Full Text] [Related]
7. Sodium ferric gluconate complex in sucrose: safer intravenous iron therapy than iron dextrans.
Faich G; Strobos J
Am J Kidney Dis; 1999 Mar; 33(3):464-70. PubMed ID: 10070910
[TBL] [Abstract][Full Text] [Related]
8. Safety of iron sucrose in hemodialysis patients intolerant to other parenteral iron products.
Charytan C; Schwenk MH; Al-Saloum MM; Spinowitz BS
Nephron Clin Pract; 2004; 96(2):c63-6. PubMed ID: 14988600
[TBL] [Abstract][Full Text] [Related]
9. Parenteral iron use in the management of anemia in end-stage renal disease patients.
Bailie GR; Johnson CA; Mason NA
Am J Kidney Dis; 2000 Jan; 35(1):1-12. PubMed ID: 10620537
[TBL] [Abstract][Full Text] [Related]
10. [Parenteral iron therapy: problems and possible solutions].
Hoigné R; Breymann C; Künzi UP; Brunner F
Schweiz Med Wochenschr; 1998 Apr; 128(14):528-35. PubMed ID: 9592894
[TBL] [Abstract][Full Text] [Related]
11. Sodium ferric gluconate complex therapy in anemic children on hemodialysis.
Warady BA; Zobrist RH; Wu J; Finan E;
Pediatr Nephrol; 2005 Sep; 20(9):1320-7. PubMed ID: 15971073
[TBL] [Abstract][Full Text] [Related]
12. Comparison of oxidative stress markers after intravenous administration of iron dextran, sodium ferric gluconate, and iron sucrose in patients undergoing hemodialysis.
Pai AB; Boyd AV; McQuade CR; Harford A; Norenberg JP; Zager PG
Pharmacotherapy; 2007 Mar; 27(3):343-50. PubMed ID: 17316146
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of iron sucrose in patients sensitive to iron dextran: North American clinical trial.
Van Wyck DB; Cavallo G; Spinowitz BS; Adhikarla R; Gagnon S; Charytan C; Levin N
Am J Kidney Dis; 2000 Jul; 36(1):88-97. PubMed ID: 10873877
[TBL] [Abstract][Full Text] [Related]
14. The safety of intravenous iron dextran (Dexferrum) during hemodialysis in patients with end stage renal disease.
Hood SA; O'Brien M; Higgins R
Nephrol Nurs J; 2000 Feb; 27(1):41-2. PubMed ID: 10852689
[TBL] [Abstract][Full Text] [Related]
15. Sodium ferric gluconate complex in the treatment of iron deficiency for patients on dialysis.
Fishbane S; Wagner J
Am J Kidney Dis; 2001 May; 37(5):879-83. PubMed ID: 11325667
[TBL] [Abstract][Full Text] [Related]
16. Is there a difference between the allergic potencies of the iron sucrose and low molecular weight iron dextran?
Sav T; Tokgoz B; Sipahioglu MH; Deveci M; Sari I; Oymak O; Utas C
Ren Fail; 2007; 29(4):423-6. PubMed ID: 17497463
[TBL] [Abstract][Full Text] [Related]
17. Addressing patient concerns about intravenous iron therapy.
Robbins KC
Nephrol Nurs J; 2003 Apr; 30(2):220-4, 258. PubMed ID: 12737000
[TBL] [Abstract][Full Text] [Related]
18. Drug insight: Safety of intravenous iron supplementation with sodium ferric gluconate complex.
Michael B; Fishbane S; Coyne DW; Agarwal R; Warnock DG
Nat Clin Pract Nephrol; 2006 Feb; 2(2):92-100. PubMed ID: 16932400
[TBL] [Abstract][Full Text] [Related]
19. The safety of intravenous iron dextran in hemodialysis patients.
Fishbane S; Ungureanu VD; Maesaka JK; Kaupke CJ; Lim V; Wish J
Am J Kidney Dis; 1996 Oct; 28(4):529-34. PubMed ID: 8840942
[TBL] [Abstract][Full Text] [Related]
20. Use of intravenous iron supplementation in chronic kidney disease: an update.
Macdougall IC; Geisser P
Iran J Kidney Dis; 2013 Jan; 7(1):9-22. PubMed ID: 23314137
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
